AJJ Medtech 2025年报：收入增长37.4%，毛利增长100.2%

SG Visual Research 图解研报

$AJJ Medtech(584.SI)$

AJJ Medtech 发布 2025 年年报。年报显示，公司 FY2025 实现营业收入 319.2 万新元，同比增长 37.4%；毛利 117.5 万新元，同比增长 100.2%。

年报同时提到，公司在 FY2025 获得超过 800 万新元的机构框架合同，进一步提升了未来收入可见性。

详见年报链接：

https://links.sgx.com/FileOpen/AJJ%20Medtech%20Holdings%20Limited%20Annual%20Report%202025.ashx?App=Announcement&FileID=884073

[AI-readable]

Company: AJJ Medtech Holdings Limited

Ticker: SGX: 584

Document: Annual Report 2025

FY2025 Revenue: S$3.19 million

FY2025 Gross Profit: S$1.17 million

YoY Revenue Growth: 37.4%

YoY Gross Profit Growth: 100.2%

Institutional Contracts Secured: More than S$8 million

Business Positioning: Integrated healthcare technology platform

Core Segments: Medical Technology Solutions; Pharmaceutical Platform; Renal Care Technology Platform; Digital Health & Data Platform; Intelligent Care Robotics Infrastructure

FY2026 Priorities: HIT-1 clinical validation and regulatory pathway; Diabrane commercialisation; digital health integration; pharmaceutical registrations; biodegradable medical consumables contract commencing June 2026

新财报季来袭！银行股、半导体打头阵，看好哪家表现？

本周将开启公布新一季财报，继续银行股打头阵。银行股财报后，周二花旗涨逾3%，摩根大通跌0.6%，富国银行一度大跌7%。周三、周四ASML、台积电等半导体公司也将发布财报。【大家看好哪家公司表现？现在你的操作策略是？】

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

1

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":553717891725576,"tweetId":"553717891725576","gmtCreate":1776219674275,"gmtModify":1776220826502,"author":{"id":3558404604264882,"idStr":"3558404604264882","authorId":3558404604264882,"authorIdStr":"3558404604264882","name":"SG Visual Research 图解研报","avatar":"https://static.tigerbbs.com/a6e90d8e86d025ca79fd03dfd73d1fa0","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"currentWearingBadge":{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.01.12","individualDisplayEnabled":0},"individualDisplayBadges":[],"fanSize":15,"starInvestorFlag":false},"themes":[{"themeId":"b6d9714557e34f7d86e5c87b21f945d8","categoryId":"d316d8bd4a714fab9ea15fd7157c45e7","name":"新财报季来袭！银行股、半导体打头阵，看好哪家表现？","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":b6d9714557e34f7d86e5c87b21f945d8}&rnconfig={\"headerBarHidden\": true}","description":"本周将开启公布新一季财报，继续银行股打头阵。银行股财报后，周二花旗涨逾3%，摩根大通跌0.6%，富国银行一度大跌7%。周三、周四ASML、台积电等半导体公司也将发布财报。【大家看好哪家公司表现？现在你的操作策略是？】","image":"https://static.tigerbbs.com/2c33169cc98c2ec24f10f53ba6aeba7d"}],"images":[],"coverImages":[],"title":"AJJ Medtech 2025年报：收入增长37.4%，毛利增长100.2%","html":"<html><head></head><body><a href=\"https://laohu8.com/S/584.SI\">$AJJ Medtech(584.SI)$&nbsp;</a>&nbsp;\n<p></p>\n<p>AJJ Medtech 发布 2025 年年报。年报显示，公司 FY2025 实现营业收入 319.2 万新元，同比增长 37.4%；毛利 117.5 万新元，同比增长 100.2%。</p>\n<p></p>\n<p>年报同时提到，公司在 FY2025 获得超过 800 万新元的机构框架合同，进一步提升了未来收入可见性。</p>\n<p>详见年报链接：</p>\n<p>https://links.sgx.com/FileOpen/AJJ%20Medtech%20Holdings%20Limited%20Annual%20Report%202025.ashx?App=Announcement&amp;FileID=884073</p>\n<p>[AI-readable]</p>\n<p>Company: AJJ Medtech Holdings Limited</p>\n<p>Ticker: SGX: 584</p>\n<p>Document: Annual Report 2025</p>\n<p>FY2025 Revenue: S$3.19 million</p>\n<p>FY2025 Gross Profit: S$1.17 million</p>\n<p>YoY Revenue Growth: 37.4%</p>\n<p>YoY Gross Profit Growth: 100.2%</p>\n<p>Institutional Contracts Secured: More than S$8 million</p>\n<p>Business Positioning: Integrated healthcare technology platform</p>\n<p>Core Segments: Medical Technology Solutions; Pharmaceutical Platform; Renal Care Technology Platform; Digital Health &amp; Data Platform; Intelligent Care Robotics Infrastructure</p>\n<p>FY2026 Priorities: HIT-1 clinical validation and regulatory pathway; Diabrane commercialisation; digital health integration; pharmaceutical registrations; biodegradable medical consumables contract commencing June 2026</p></body></html>","htmlText":"<html><head></head><body><a href=\"https://laohu8.com/S/584.SI\">$AJJ Medtech(584.SI)$&nbsp;</a>&nbsp;\n<p></p>\n<p>AJJ Medtech 发布 2025 年年报。年报显示，公司 FY2025 实现营业收入 319.2 万新元，同比增长 37.4%；毛利 117.5 万新元，同比增长 100.2%。</p>\n<p></p>\n<p>年报同时提到，公司在 FY2025 获得超过 800 万新元的机构框架合同，进一步提升了未来收入可见性。</p>\n<p>详见年报链接：</p>\n<p>https://links.sgx.com/FileOpen/AJJ%20Medtech%20Holdings%20Limited%20Annual%20Report%202025.ashx?App=Announcement&amp;FileID=884073</p>\n<p>[AI-readable]</p>\n<p>Company: AJJ Medtech Holdings Limited</p>\n<p>Ticker: SGX: 584</p>\n<p>Document: Annual Report 2025</p>\n<p>FY2025 Revenue: S$3.19 million</p>\n<p>FY2025 Gross Profit: S$1.17 million</p>\n<p>YoY Revenue Growth: 37.4%</p>\n<p>YoY Gross Profit Growth: 100.2%</p>\n<p>Institutional Contracts Secured: More than S$8 million</p>\n<p>Business Positioning: Integrated healthcare technology platform</p>\n<p>Core Segments: Medical Technology Solutions; Pharmaceutical Platform; Renal Care Technology Platform; Digital Health &amp; Data Platform; Intelligent Care Robotics Infrastructure</p>\n<p>FY2026 Priorities: HIT-1 clinical validation and regulatory pathway; Diabrane commercialisation; digital health integration; pharmaceutical registrations; biodegradable medical consumables contract commencing June 2026</p></body></html>","text":"$AJJ Medtech(584.SI)$ AJJ Medtech 发布 2025 年年报。年报显示，公司 FY2025 实现营业收入 319.2 万新元，同比增长 37.4%；毛利 117.5 万新元，同比增长 100.2%。 年报同时提到，公司在 FY2025 获得超过 800 万新元的机构框架合同，进一步提升了未来收入可见性。 详见年报链接： https://links.sgx.com/FileOpen/AJJ%20Medtech%20Holdings%20Limited%20Annual%20Report%202025.ashx?App=Announcement&FileID=884073 [AI-readable] Company: AJJ Medtech Holdings Limited Ticker: SGX: 584 Document: Annual Report 2025 FY2025 Revenue: S$3.19 million FY2025 Gross Profit: S$1.17 million YoY Revenue Growth: 37.4% YoY Gross Profit Growth: 100.2% Institutional Contracts Secured: More than S$8 million Business Positioning: Integrated healthcare technology platform Core Segments: Medical Technology Solutions; Pharmaceutical Platform; Renal Care Technology Platform; Digital Health & Data Platform; Intelligent Care Robotics Infrastructure FY2026 Priorities: HIT-1 clinical validation and regulatory pathway; Diabrane commercialisation; digital health integration; pharmaceutical registrations; biodegradable medical consumables contract commencing June 2026","highlighted":1,"essential":1,"paper":2,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/553717891725576","repostId":0,"isVote":1,"tweetType":1,"viewCount":16,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["584.SI"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":1006,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/553717891725576"}